Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review

Author(s): Mahmoud A. Ebada*, Souad Alkanj, Mohamed Ebada, Ahmed H. Abdelkarim, Ahmed Diab, Mohamed A.E. Aziz, Ahmed M. Soliman, Notila Fayed, Eshak I. Bahbah, Ahmed Negida.

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 18 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Levetiracetam, a novel antiepileptic drug, has shown antidyskinetic effects in experimental animal models of Parkinson's disease (PD). The tolerability and efficacy of levetiracetam in reducing the levodopa-induced dyskinesia (LID) in PD patients have not been established. Therefore, this study aims to synthesize evidence from published prospective clinical trials about the efficacy of levetiracetam for the management of LID in PD patients.

Methods: We followed the PRISMA statement guidelines during the preparation of this systematic review. A computer literature search of PubMed, EBSCO, Scopus, MEDLINE, and the web of science was carried out. We selected prospective clinical trials assessing the anti-dyskinetic efficacy of levetiracetam for treating LID in patients with PD. The Abnormal Involuntary Movement Scale (AIMS), Clinical Global Impression Score (GCI), UPDRS III, and UPDRS IV were considered as the primary outcome measures; their data were extracted and reviewed.

Results: Our review included seven clinical trials with a total of 150 patients. Of them, three studies were randomized controlled trials, and the remaining were open-label single arm trials. Four studies reported poor tolerability of the levetiracetam with mild anti-dyskinetic effects. Levetiracetam slightly improved the UPDRS-IV and AIMS scores with small effect size. In the remaining three studies, levetiracetam failed to exhibit any anti-dyskinetic effects.

Conclusion: Current evidence does not support the efficacy of the levetiracetam for treating LID in PD patients, however, due to the limited number of published randomized control trials (RCTs), further RCTs are required.

Keywords: Dyskinesia, levodopa-induced dyskinesia, levetiracetam, parkinson's disease, neurodegenerative disease, catechol- O-methyltransferase.

[1]
Negida A, Elfil M, Attia E, et al. Caffeine; the forgotten potential for parkinson’s disease. CNS Neurol Disord Drug Targets 2017; 16(6): 652-7.
[2]
Fatima A, Jyoti S, Siddique YH. Models of Parkinson’s disease with special emphasis on drosophila melanogaster. CNS Neurol Disord Drug Targets 2018; 17(10): 757-66.
[3]
de Farias CC, Maes M, Bonifacio KL, et al. Parkinson’s disease is accompanied by intertwined alterations in iron metabolism and activated immune-inflammatory and oxidative stress pathways. CNS Neurol Disord Drug Targets 2017; 16(4): 484-91.
[4]
Radad K, Moldzio R, Al-Shraim M, Kranner B, Krewenka C, Rausch W-D. Recent advances on the role of neurogenesis in the adult brain: Therapeutic potential in Parkinson’s and Alzheimer’s diseases. CNS Neurol Disord Drug Targets 2017; 16(7): 740-8. Available from http: //www.ncbi.nlm.nih.gov/pubmed/ 28641510
[5]
Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets 2017; 16(4): 425-39.
[6]
Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature [Internet] 1988; Jul 28; 334(6180): 345-8. Available from.http: //www.nature.com/doifinder/10.1038/334345a0
[7]
Ohno Y, Tokudome K. Therapeutic role of synaptic vesicle glycoprotein 2A (SV2A) in modulating epileptogenesis. CNS Neurol Disord Drug Targets 2017; 16(4): 463-71.
[8]
Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson’s disease - clinical aspects.In: Movement disorders [Internet] Elsevier; 1981 p 96-122 Available from. http: //linkinghub.elsevier.com/retrieve/pii/B9780407022959500126
[9]
Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry 1971(1); 34(6): 668-73.
[10]
Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov Disord 2005; 20(3): 342-4.
[11]
Nagatsu T, Sawada M. L-dopa therapy for Parkinson’s disease: Past, present, and future. Parkinsonism Relat Disord 2009; 15: S3-8.
[12]
Schrag A. Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 2005; 4(6): 366-70.
[13]
Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000; 23: S86-91.
[14]
Klitgaard H. Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Epilepsia 2008; 42: 13-8.
[15]
Georg MD, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000; 42(4): 281-5.
[16]
Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136(5): 659-72.
[17]
Hill MP, Brotchie JM, Crossman AR, et al. Levetiracetam interferes with the l-dopa priming process in mptp-lesioned drug-naive marmosets. Clin Neuropharmacol 2004; 27(4): 171-7.
[18]
Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004; 485(1-3): 159-64.
[19]
Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003; 18(11): 1301-5.
[20]
Dyskinesia L, Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in parkinson disease patients with 2006 29(3): 148- 53.
[21]
Wong KK, Alty JE, Goy AG, Raghav S, Reutens DC, Kempster PA. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson’s disease. Mov Disord 2011; 26(8): 1552-5.
[22]
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Vol. Version 5., Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series 2008.
[23]
Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011; 26(2): 264-70.
[24]
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study 2006; 21(8): 2005-7.
[25]
Wolz M, Lohle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. J Neural Transm 2010; 117(11): 1279-86.
[26]
Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2005; 20(9): 1205-9.
[27]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[28]
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study. Mov Disord 2006; 21(8): 1219-21.
[29]
Francisco S. Levetiracetam in l -dopa-induced dyskinesia. 2005; 28(2): 102-3.
[30]
Deshpande LS, DeLorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol 2014; 5: 3389.
[31]
Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101(26): 9861-6.
[32]
Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006; 26(4): 1303-13.
[33]
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16(3): 448-58.
[34]
Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63(2): 205.
[35]
Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011; 26(2): 264-70.
[36]
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study. Mov Disord 2006; 21(8): 1219-21.
[37]
Wolz M, Löhle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. J Neural Transm 2010; 117(11): 1279-86.
[38]
Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry 2007; 4(7): 28-37.
[39]
Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003; 18(11): 1301-5.
[40]
Hill MP, Brotchie JM, Crossman AR, et al. Levetiracetam Interferes with the l-dopa priming process in mptp-lesioned drug-naive marmosets. Clin Neuropharmacol 2004; 27(4): 171-7.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 4
Year: 2019
Page: [317 - 325]
Pages: 9
DOI: 10.2174/1871527318666190314101314
Price: $58

Article Metrics

PDF: 43
HTML: 3